Department of Neurosurgery, National Neuroscience Institute, Singapore; Division of Neurosurgery, Department of Surgery, National University Hospital, Singapore.
Division of Neurosurgery, Department of Surgery, National University Hospital, Singapore.
J Clin Neurosci. 2021 Nov;93:227-230. doi: 10.1016/j.jocn.2021.09.002. Epub 2021 Sep 24.
Alveolar soft part sarcoma (ASPS) has the highest incidence of brain metastasis amongst sarcomas. There is a paucity of literature published focusing on radiation therapy for this condition. This is a single centre retrospective review of the treatment of three patients with 12 ASPS brain metastasis using single dose stereotactic radiosurgery (SRS). Five lesions were treated with low (<25 Gy) and seven with high (≥25 Gy) dose. Four lesions had a volume of >1.5 cm and were defined as large, while seven had a volume of ≤0.5 cm and were defined as small. The local tumor control as well as the clinical complication rates were studied. There was a statistically significant relation between treatment dose and tumor control rate. All large tumors treated with low dose recurred and required surgical removal within two months following SRS, while the large lesion treated with high dose recurred after 11 months. Five of the six small tumors treated with high doses were controlled, while the sixth required retreatment and was stable thereafter. No patient suffered from undue symptomatic radiation effects. The success rate following SRS for small ASPS metastases treated with high doses seems to be sufficient to justify the treatment. The short time for large tumor to recur, significant increase in tumor size requiring surgical removal of the tumors, makes low dose SRS unattractive. Based on this limited patient population, it seems that high dose SRS should be used for all ASPS brain metastases except for large tumors deemed surgically accessible.
腺泡状软组织肉瘤 (ASPS) 是肉瘤中脑转移发生率最高的肿瘤。目前针对这种疾病的放射治疗的文献报道非常少。这是一项单中心回顾性研究,研究了 3 例 ASPS 脑转移患者共 12 个病灶接受单次剂量立体定向放射外科治疗 (SRS) 的情况。5 个病灶接受低剂量 (<25Gy) 治疗,7 个病灶接受高剂量 (≥25Gy) 治疗。4 个病灶体积>1.5cm,定义为大病灶,7 个病灶体积≤0.5cm,定义为小病灶。研究了局部肿瘤控制率和临床并发症发生率。治疗剂量与肿瘤控制率之间存在统计学显著关系。所有接受低剂量治疗的大病灶均复发,并在 SRS 后两个月内需要手术切除,而接受高剂量治疗的大病灶在 11 个月后复发。6 个小病灶中,有 5 个接受高剂量治疗的病灶得到了控制,而第 6 个病灶需要再次治疗,此后一直保持稳定。没有患者出现过度的症状性放射效应。对于接受高剂量 SRS 治疗的小 ASPS 转移灶,其成功率似乎足以证明这种治疗是合理的。大病灶复发时间短,肿瘤体积显著增大,需要手术切除肿瘤,使得低剂量 SRS 变得不那么有吸引力。基于这一有限的患者群体,似乎除了认为可手术切除的大病灶外,所有 ASPS 脑转移瘤都应采用高剂量 SRS 治疗。